NovaPrint Medical Completes Tens of Millions RMB Series A Financing to Advance Clinical Translation of 3D-Bioprinted Tissue Repair Products

Novaprint Therapeutics Suzhou Co., Ltd. (hereinafter referred to as “Novaprint Regenerative Medicine”), a leading domestic enterprise in bio-3D printing, has recently completed its Series A financing round amounting to tens of millions of yuan. The round was led by YuanBio Venture Capital, with Wuzhong High-Tech Innovation Venture Capital participating as a co-investor. The proceeds will be utilized to advance the research and development and clinical registration of two innovative bio-3D printed tissue repair products, strengthen talent team building, and further expand the company’s R&D pipeline.

Since its establishment, Novaprint Therapeutics has been dedicated to the field of regenerative medicine, focusing on tissue engineering and leveraging bio-3D printing technology as its cornerstone to meet the urgent market demand for regenerative artificial tissues. Skin, bone, and cartilage hold a significant position in the overall market for regenerative artificial tissues, accounting for approximately 30%. Data indicates that there are up to 9.75 million patients with skin defects and 13 million patients with bone and cartilage injuries in China annually. Many of these patients require healthy skin, bone, and cartilage tissues for repair and transplantation to alleviate their conditions. With the continuous advancement of additive manufacturing technologies, bio-3D printing, which enables the fabrication of personalized regenerative tissue-engineered products, has been recognized by both academia and industry as one of the technologies closest to clinical translation and large-scale commercialization. It is regarded as a crucial technological support driving the personalization, precision, minimally invasive nature, and remote accessibility of healthcare in the 21st century, and has been included by the government in the "Made in China 2025" development plan.

Biological 3D printing technology is the core competitiveness of Novaprint Therapeutics. Novaprint Therapeutics has independently developed the Organ Printing United System (OPUS), a biological 3D printing technology platform. OPUS adopts novel high-precision, multi-process, and multi-material integrated printing technology, compatible with various bio-printing materials and cell-laden bioinks. It achieves precise micro- and nano-fabrication through computer-aided bionic design, effectively constructing a microenvironment conducive to long-term cell survival and proliferation. This enables regeneration and functional reconstruction ranging from simple two-dimensional tissue structures to complex architectures, representing a truly clinically practical and innovative biological 3D printing solution. Leveraging the advanced capabilities of this platform, Novaprint Therapeutics is deeply engaged in developing comprehensive biological 3D printing solutions and innovative medical devices. Currently, the company has established a product portfolio focused on therapeutic areas such as bone repair and skin repair, meeting the diverse clinical needs for tissue restoration in the current market. Notably, two breakthrough products—biologically 3D-printed bone repair scaffolds and biologically 3D-printed skin repair constructs—have completed preclinical studies and are poised to enter clinical trials. Upon market launch, these two products are expected to provide new solutions to clinical challenges in bone and skin repair. Furthermore, Novaprint Therapeutics will continue to uphold its strategy of medical-engineering collaboration, constantly expanding its R&D pipeline to deliver innovative medical device products targeting indications with urgent clinical needs.

Regarding this financing round, Dr. Yang Xi, Co-founder and CEO of Novaprint Therapeutics, stated: “Novaprint Therapeutics is an innovative enterprise dedicated to bio-3D printing. With the strong support from YuanBio Venture Capital and Wuzhong High-Tech Venture Capital in this round, we will further accelerate the clinical registration progress of our bio-3D printed tissue repair products, enabling Novaprint Therapeutics to maintain its rapid momentum in this field. Furthermore, this financing will continue to enhance our R&D and innovation capabilities, expand our team, and broaden our development pipeline. We will remain steadfast in our original commitment to applying bio-3D printing to clinical treatment, upholding independent innovation and medical-engineering collaboration. Through innovative products and an open cooperative model, we aim to serve the broad field of tissue repair, alleviate patient suffering, improve quality of life, and ‘print’ health.”

Novaprint Therapeutics, established in September 2016, is a National High-Tech Enterprise specializing in the field of bioprinting. It has been recognized as both a Gusu Leading Talent Enterprise and a Suzhou Industrial Park Leading Talent Enterprise. The company is built upon its proprietary OPUS technology-based bioprinting platform, aiming to provide internationally leading comprehensive solutions for bioprinting. Leveraging this platform, Novaprint develops and manufactures bio-printed artificial tissues and medical devices urgently needed in clinical practice. The company holds 13 national patents and 8 software copyrights, and has participated in the development of three industry group standards. Highly regarded by both academic and industrial communities, Novaprint was among the earliest members of the Additive Manufacturing Alliance under the Ministry of Industry and Information Technology (MIIT). It is also a member of the 3D Printing Professional Committee of the China Medical Device Industry Association and a participating entity in drafting association standards for the China Medical Device Industry Association.

YuanBio Venture Capital is an investment firm focused on early- and growth-stage healthcare and life sciences companies. Headquartered in Suzhou BioBAY, it maintains a global reach. The firm currently manages approximately RMB 6 billion in assets and has completed investments in more than 100 high-quality projects, primarily spanning new drug development, medical devices, in vitro diagnostics, and healthcare services. It has delivered substantial investment returns and has been repeatedly recognized as one of the Top 10 venture capital funds in China’s healthcare sector and as one of the most active healthcare investors in China. YuanBio Venture Capital brings together a team of seasoned professional investors and world-class scientific advisors, with extensive experience in entrepreneurship, venture capital, and corporate operations within the biopharmaceutical industry and related fields. Leveraging its focused strategy and rich industry resources, YuanBio Venture Capital is committed to becoming one of the most successful healthcare and pharmaceutical venture capital funds in China.

Jiangsu Wuzhong High-Tech Venture Capital Co., Ltd., established in 2006, is a wholly-owned subsidiary initiated by Wuzhong Group. With two core business segments—high-tech project investment and industrial real estate development and operation—the company is fully committed to supporting the high-quality development of China’s regional economies. Adhering to a “Base + Fund” core operational model, Wuzhong High-Tech leverages the Group’s full-industry-chain advantages to facilitate the transition from old to new growth drivers in urban industries. By formulating industrial promotion strategies and implementing industrial development plans, it cultivates the venture capital industry and supports enterprise growth, thereby safeguarding businesses throughout their entire life cycles and facilitating regional industrial transformation and upgrading.